F52C12.1 Antibody

Overview of CCAntibody

CC12.1 is a human monoclonal antibody isolated from a SARS-CoV-2-infected patient. It targets the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein and exhibits potent neutralization by blocking ACE2 receptor interactions .

Key Features:

• Germline Origin: IGHV3-53 with minimal somatic hypermutation (1% nucleotide-level changes) .

• Light Chain: IGKV1-9 and IGKJ3 .

• Binding Affinity: 17 nM (K_d) for SARS-CoV-2 RBD .

• Epitope: Overlaps with the ACE2 binding site but does not compete with the cross-reactive antibody CR3022 .

Table 1: Comparison of CC12.1 with Other SARS-CoV-2 Antibodies

Data sourced from structural studies in references .

2.2. Mechanism of Neutralization

• ACE2 Blockade: CC12.1 binds exclusively to the "up" conformation of the RBD, sterically hindering ACE2 engagement .

• Low Mutational Burden: Minimal somatic hypermutation suggests natural immune efficacy without extensive affinity maturation .

Therapeutic Implications

CC12.1 is part of a broader class of public antibodies that dominate early SARS-CoV-2 immune responses due to germline-encoded efficacy. Key applications include:

• Vaccine Design: Informing epitope-focused immunogens .

• Cocktail Therapies: Pairing with antibodies targeting non-overlapping epitopes (e.g., CR3022) to prevent viral escape .

Research Limitations and Future Directions

• Structural Rigidity: Short CDR H3 limits adaptability against emerging variants .

• Synergy Potential: Combinatorial use with Fc-engineered antibodies (e.g., non-fucosylated formats) could enhance effector functions like ADCC .